News articles about Achillion Pharmaceuticals (NASDAQ:ACHN) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Achillion Pharmaceuticals earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.0378389250229 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the headlines that may have impacted Accern Sentiment’s rankings:

Achillion Pharmaceuticals (NASDAQ:ACHN) opened at 3.825 on Tuesday. The stock’s 50 day moving average is $4.59 and its 200 day moving average is $4.21. The firm’s market capitalization is $523.11 million. Achillion Pharmaceuticals has a 1-year low of $3.15 and a 1-year high of $9.19.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.16). During the same quarter in the previous year, the company posted ($0.14) earnings per share. Analysts predict that Achillion Pharmaceuticals will post ($0.66) EPS for the current fiscal year.

ACHN has been the topic of several recent research reports. Leerink Swann upgraded shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $4.00 to $6.00 in a research note on Thursday, May 18th. BidaskClub upgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Chardan Capital lowered their price target on shares of Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 9th. Finally, Maxim Group set a $7.00 price target on shares of Achillion Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 9th. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $8.13.

WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Achillion Pharmaceuticals (ACHN) Stock Price” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2017/09/12/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-achillion-pharmaceuticals-achn-stock-price.html.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Insider Buying and Selling by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Stock Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.